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Polyomavirus nephropathy (PVN) mainly caused by BK virus (BKV) remains the most common productive
viral infection of the kidney. Over the past decade, clinical interest often focused on BK viremia and
viruria as the diagnostic mainstays of patient management. The purpose of this review is to discuss viral
nephropathy in the context of BK viremia and viruria and new strategies to optimize diagnostic accuracy
and patient management. The emerging roles of polyomaviruses in oncogenesis, salivary gland disease,
and post-bone marrow transplantation as well as novel Polyomavirus strains are highlighted.
Recent findings
Areas of investigation include proposals by the Banff working group on the classification of PVN and
studies on PVN progression and resolution, including the role cellular immune responses may play during
reconstitution injury. New noninvasive strategies to optimize the diagnosis of PVN, that is, the urinary
‘polyomavirus-haufen’ test and mRNA expression levels for BKV in the urine, hold great promise to
accurately identify patients with viral nephropathy. Tools are now available to separate ‘presumptive’ from
‘definitive’ disease in various patient cohorts including individuals post-bone marrow transplantation. Recent
observations also point to a currently underrecognized role of polyomaviruses in oncogenesis post-
transplantation and salivary gland disease in patients with HIV-AIDS.
Summary
This review summarizes recent studies on PVN and the significance of the BKV strain in disease. Current
paradigms for patient management post-(renal) transplantation are discussed in the setting of new
observations. Issues that still require clarification and further validation are highlighted.
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Modern immunosuppression has led to improved
allograft survival and optimized treatment of
autoimmune diseases, such as multiple sclerosis.
However, new therapeutic strategies have also
introduced previously uncommon side-effects. For
example, polyomaviruses of the BK strain, pre-
viously ‘in-search of a disease’, have now found
what they were looking for, that is, they can cause
polyomavirus nephropathy (PVN) or hemorrhagic
cystitis. In addition, increasing evidence links the
BK-virus (BKV) strain to oncogenesis in transplant
recipients and possibly salivary gland disease in
HIV-infected patients. In recent years, several novel
human polyomavirus strains associated with some
unusual pathologic changes have also been ident-
ified.
Thus, although much has been learned about
polyomaviruses, new questions have arisen as well.This review focuses on clinically significant aspects
of polyomavirus infections with emphasis on the
polyoma-BKV strain and PVN. Old paradigms are
revisited in the light of new findings and ongoing
trials.Volume 20  Number 3  June 2015
KEY POINTS
 PVN is morphologically defined by the presence of
viral replication in the renal parenchyma and varying
degrees of virally induced acute tubular injury.
 Based on morphology, PVN can be classified into
disease grades 1–3 with disease resolution and
favorable outcome in early disease grade 1 and a
high risk of graft failure in grade 3.
 Novel urine-based assays allow for an accurate
noninvasive diagnosis of PVN: the urinary
polyomavirus-Haufen test and PCR assays targeting
BKV mRNA expression levels. The concept of
‘presumptive’ and ‘definitive’ PVN can now be
revisited: is it the same entity?
 The intriguing concept of so-called immune
reconstitution type of graft inflammation during
resolving PVN needs further studies: does it exist?
 BKV is associated with oncogenesis and potentially
salivary gland disease in immunocompromised
patients.
Polyomaviruses and disease Nickeleit and SinghHUMAN POLYOMAVIRUS STRAINS AND
DISEASE
Polyomaviruses are ubiquitous, small, double-
stranded DNA viruses that exist in symbiosis with
humans and animals. In recent years, the family of
human polyomaviruses has grown to 13 members,
and it will likely expand further due to the intro-






After a primary infection early in life, polyoma-
viruses often establish latency in the genitourinary
tract as well as other anatomic sites. Several human
polyomavirus strains can coexist in the same host
organism and even in the same organ, such as the
kidney. Seroprevalence, depending on the viral
strain and the patient age, ranges from 20% to
greater than 90% [3
&&
]. Latent polyomavirus strains,
alone or in combination, can undergo episodes of
self-limiting asymptomatic reactivation with viruria
and viremia [4,5,6
&&
]. However, despite a high
prevalence of latent polyomavirus infections and
transient asymptomatic activation of latent polyo-
maviruses, manifest viral disease is rare. It is linked
to five of the 13 polyomavirus strains and limited
to patients with impaired immune surveillance,







The ‘disease-causing’ strains show different patterns
of injury: neoplasms without productive viral
replication (e.g., Merkel cell carcinomas) and pro-
ductive viral infections with tissue injury but with-
out neoplasms (e.g., PVN and progressive multifocal
leukoencephalopathy). Proliferative lesions and1087-2418 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseneoplasms are mainly caused by two recently
described human polyomavirus strains: trichodys-
plasia spinulosa-associated polyomavirus and Mer-
kel cell polyomavirus that can cause tumors of the
skin. Emerging evidence also links the polyoma-BKV
strain to oncogenesis in rare cases [12–19]. Pathol-
ogy of productive infections with tissue injury and
varying degrees of inflammation is seen with poly-
oma-BK and JC viruses, the first two human poly-
omaviruses described in 1971 [20,21]. BKV induces
PVN and hemorrhagic cystitis. In addition, BKV
seems to be linked to salivary gland inflammation
and sclerosis in HIV-infected patients [9]. JC virus
causes lytic brain lesions, that is, progressive multi-
focal leukoencephalopathy [22–26]. A productive
infection with the recently described New Jersey
polyomavirus was seen in a pancreas transplant
recipient [2
&
]. The patient presented with acute
onset retinal blindness and vasculitic myopathy
caused by viral replication in endothelial cells.
Why certain polyomavirus strains cause disease in
some organs while sparing others harboring the
same strain in a latent state is unknown, such as
JC virus causing brain lesions/progressive multifocal
leukoencephalopathy but hardly ever causing PVN
despite a high prevalence of latent JC virus in the
renal parenchyma. In the following sections, we
focus our discussion on PVN and BK virus-associated
diseases.POLYOMAVIRUS NEPHROPATHY
PVN is typically found in renal allografts and only
rarely in native kidneys [27
&
]. Viral nephropathy is
primarily caused by the BKV strain and, in approxi-
mately 10–20% of cases, by simultaneous coactiva-
tion of BK and JC viruses. Cases of only JC virus or
SV40 virus-induced PVN are rare.
The diagnosis of PVN, sometimes also referred to
as ‘definitive’ PVN, requires morphologic evidence
of polyomavirus replication in the renal paren-
chyma by biopsy or alternatively by urinary poly-
omavirus-haufen testing (see in further sections)
[28–32,33
&
]. Although helpful in identifying
patients at increased risk, other laboratory assays
including quantitative PCR testing are not well
suited for rendering a definitive diagnosis of PVN.
Patients with PVN do not show symptoms of a
generalized infection, the urine sediment is bland
and renal function, that is, the serum creatinine
levels, can be normal.
At present, the incidence of PVN in renal allog-
raft recipients is approximately 4% with broad
transplant center variations; it is highest in ABO-
incompatible grafts (18%) [34,35]. Overall, risk fac-
tors for PVN are only poorly defined, in particular,rved. www.co-transplantation.com 349
Pathologythe striking prevalence for renal allografts. Con-
ditions promoting PVN include intense long-term
immunosuppression often including tacrolimus
and mycophenolate mofetil (MMF); transplantation
of an allograft from a BKV seropositive donor into a
seronegative recipient; prior episodes of acute renal
allograft rejection; induction therapy with anti-
thymocyte globulin; and older age of male graft
recipients among others [6
&&
,36]. Interestingly,
cyclosporine seems to have a suppressive effect on
polyomavirus replication, whereas tacrolimus and
MMF-based immunosuppression, introduced in the
mid-1990s when PVN emerged as a severe com-
plication, is tightly linked to viral activation and
disease [37–41]. Surprisingly, nonrenal allograft
recipients on high-dose tacrolimus and MMF rarely
develop PVN in their native kidneys, and, vice versa,
patients with kidney transplants on cyclosporine,
azathioprine, or sirolimus also sporadically present
with viral nephropathy [6
&&
]. Thus, multiple ‘hits’
with tacrolimus and MMF-based therapy represent-
ing only one hit are required to provide the right
window of opportunity for polyomavirus replica-
tion in the renal parenchyma. Smoldering subclin-
ical graft inflammation and/or abnormalities of
dendritic cells or natural killer cell/T-cell activation
might also be significant factors promoting PVN
[42,43,44
&&
]. In particular, an abundance of BK-
virus-specific T cells seems to be associated with
control of polyomavirus replication, prevention
of PVN, or effective disease resolution [45–48].
Whether or not these intriguing latter observations
will, indeed, result in novel targeted ‘immunothera-
pies’ remains to be determined [49].POLYOMAVIRUS NEPHROPATHY
PHENOTYPES
PVN is defined morphologically by intrarenal poly-
omavirus replication, mainly in tubular epithelial
cell nuclei, that leads to host cell lysis and release of
mature daughter virions into the tubular lumens.
Thus, PVN is a form of virally induced tubular injury
that can range from minimal, that is, polyomavirus
replication in rare tubular cells only, to marked, that
is, polyomavirus replication in many tubules with
marked cell lysis and acute tubular necrosis (ATI)
[29]. Minimal and early stages of PVN present with
normal renal function and may not show intranu-
clear viral inclusion bodies, ATI, or significant renal
injury. In such cases, a diagnosis can only be estab-
lished by immunohistochemistry, usually with an
antibody directed against the SV40-T antigen or by
in-situ hybridization [33
&
]. Marked PVN with ATI
typically presents clinically with elevated serum
creatinine levels and histologically with edema,350 www.co-transplantation.cominflammation, and, in protracted chronic cases,
interstitial fibrosis.
Despite the marked differences in morphology
and clinical presentation, PVN has traditionally not
been systematically subtyped into disease grades.
However, does ‘a’ mere diagnosis of PVN provide
optimal diagnostic/prognostic information? Can
PVN phenotypes possibly predict differences in
clinical presentation and outcome [50–53]? These
questions were the impetus to form a multicenter
‘Banff working group’ on PVN with the goal to
define clinically relevant PVN disease grades based
on histologic findings in graft biopsies. Efforts
resulted in initial data presentation at the 2013
Banff meeting in Brazil [54]. Utilizing complex stat-
istical analyses from a cohort of nearly 200 PVN
study cases, the Banff working group has proposed
three PVN disease grades based on the severity of
polyomavirus replication and the Banff ‘ci’ intersti-
tial fibrosis scores (Fig. 1). PVN grade 1 with limited
histologic polyomavirus replication and minimal
fibrosis was found early post-grafting, often without
significant dysfunction, and with a 2-year graft sur-
vival rate of 90%. In contrast, PVN disease grade 2
and, in particular, grade 3, the latter characterized
by marked viral injury and pronounced fibrosis,
were both diagnosed more than 6–12 months
post-transplantation, usually in patients with acute
graft failure. Graft outcome was also less favorable
(30% failure rate in grade 2 and 50% in grade 3).
In addition, PVN grading seems to provide better
insight into disease resolution seen in up to 80% in
PVN grade 1 and 40–50% in grade 3 (unpublished
personal observation). These findings, although
preliminary, outline the benefits of systematic
PVN grading: enhancement of comparative analyses
and improvement in predicting clinical presen-
tation and outcome. Thus, all cases of ‘definitive’
PVN are not equal and, most notably, not all cases of
‘definitive’ PVN have an ominous prognosis.
A poorly defined diagnostic aspect, in particular,
considering treatment strategies based on the
reduction of immunosuppression, is the concur-
rence of PVN and acute rejection [55,56
&&
]. Applying
previously published diagnostic criteria, we found
acute rejection in 10–15% of our cases at the time of
initial PVN diagnosis. Rejection as a possible con-
tributing factor of graft dysfunction and failure in
PVN is suggested by data from the Weill Cornell
Medical Center, New York, New York, USA. Dadha-
nia et al. [57] reported graft deterioration in those
cases of PVN presenting with elevated urinary gran-
zyme B mRNA levels that were similar to titers seen
in control cohorts with acute rejection. Also, PVN
with marked tubulitis, one possible sign of concur-
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PathologyPOLYOMAVIRUS NEPHROPATHY:
PERSISTENT AND RESOLVING
Very little information is known about the histo-
logic changes occurring during persistent and
resolving PVN. As commonly believed, is marked
chronic allograft injury with interstitial fibrosis and
tubular atrophy, indeed, a typical endpoint in all
stages of PVN? Does reconstitution immune injury
with pronounced graft inflammation exist, and, if
so, is it a typical feature of resolving PVN?
Menter et al. [56
&&
] published the first histology-
based study on resolving PVN in a cohort of patients
initially diagnosed in early and florid disease stages;
during follow-up, significant graft fibrosis and
tubular atrophy was not seen at time of disease
resolution. We have made similar observations:
PVN often does not cause relevant scarring.
Possible immune reconstitution-associated graft
inflammation during resolving PVN in a patient
under ‘low-dose’ immunosuppression was first
suggested by researchers from Basel, Switzerland,
in 2007 [59]. Subsequently, Menter et al. [56
&&
] pre-
sented data from patients with resolving/cleared
PVN and graft inflammation mimicking Banff
type I tubulointerstitial cellular rejection. The
changes were interpreted as immune reconstitu-
tion-associated acute interstitial nephritis, antirejec-
tion therapy was withheld, and outcome was good
[56
&&
]. In contrast, we have not found significant
inflammation in a set of protocol biopsies from
patients with resolved PVN (unpublished data). In




























FIGURE 2. Schematic graph with estimates of BK-virus activation
shedding and viral nephropathy/PVN postrenal transplantation. A
percentage of patients, ‘definitive’ PVN develops in only a small s
polyomavirus-haufen test is almost exclusively seen in patients with
diagnosis in patients clinically presenting with evidence of BK-viru
352 www.co-transplantation.comthoroughly study immune reconstitution injury
under ‘low-dose’ immunosuppression: does it exist;
if so, is it a common and prominent event; is it
linked to persistent/residual intrarenal polyomavi-
rus replication and a form of polyomavirus-driven
interstitial nephritis; are graft-infiltrating lympho-
cytes allospecific or BKV specific; and could inflam-
mation possibly represent an unusual form of
subclinical rejection?
CURRENT PARADIGMS AND SCREENING
TOOLS GUIDING PATIENT MANAGEMENT
All patients with PVN have evidence of polyomavi-
rus activation, most often BKV, including viremia
and viruria. Current clinical screening recommen-
dations for the risk assessment of PVN postrenal
transplantation are based on this paradigm
[28,60–63]. Conversely, however, only few patients
with BK viremia and BK viruria have or will develop
disease, that is, ‘definitive’ PVN, as transient asymp-
tomatic reactivation of latent polyomaviruses is
common along the lower urinary tract (Fig. 2).
For example, in a cohort of 100 renal allograft
recipients from the University of North Carolina at
Chapel Hill (UNC), none of whom developed PVN,
we found BK viruria in 51–64% (based on PCR
testing or the detection of decoy cells, respectively)
[30]. BK viremia is not uncommon either. It was
detected in 4% of liver, 7% of heart transplant
recipients, in up to 65% of pediatric patients with
hemorrhagic cystitis post-bone marrow transplan-





, that is, BK viruria, BK viremia, urinary polyomavirus-haufen
lthough viruria and viremia are detected in a high
ubgroup of ‘viral activators’. Note: A positive urinary
definitive PVN and can help to render a noninvasive
s activation. BKV, BK virus; PVN, polyomavirus nephropathy.
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Polyomaviruses and disease Nickeleit and Singhsalivary gland disease (personal observation), all of
whom usually do not develop PVN [11
&&
,30,64–66].
In renal allograft recipients, BK viremia (based on
quantitative PCR testing) has been reported in 16–
54% of patients in large consecutively studied
cohorts, only 14–46% of whom present with evi-
dence of ‘definitive’ PVN [36,53,67,68]. In a pro-
spective study at UNC including routine urinary
polyomavirus-haufen testing (see in the next sec-
tion), we found BK viremia in 114/399 (29%) kidney
transplant recipients of whom only 36/114 (32%)
developed ‘definitive’ PVN (unpublished data).
In order to improve the positive predictive value
of PCR-based BK-viremia assays, threshold levels of
greater than 4 log10 copies/ml have been advocated.
However, problems remain. PCR assays are not
standardized rendering general recommendations
based on threshold levels problematic. Few patients
with PVN may be negative for BK viremia (PVN
caused by JC virus; PCR assay targeting BK gene
sequences with polymorphism/mutations). Other
patients with PVN may present at time of initial
diagnosis with very low BK-viremia titers (occasion-
ally as low as 2 log10, BK copies/ml) [30,67,68].
Conversely, even high BK-viremia titers do not
necessarily allow for a diagnosis of ‘definitive’
PVN as shown in a cohort of 17 disease-free patients

















FIGURE 3. Cases of ‘definitive’ polyomavirus nephropathy (PVN
urine and plasma markers. Correlation of the degree of marker e
severity of PVN –intrarenal polyomavirus replication, that is, the n
biopsy sample with PVN (x-axis). (a) Urinary polyomavirus-haufen
(BKV): number of BKV copies/ml urine; (c) plasma PCR for BKV: n
number of decoy cells/ThinPrep cytology preparation. Regression
r values are depicted. Adapted from [31&&].
1087-2418 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseand in 3/17 UNC patients (18%) collected in a
control cohort [30,69
&
]. Similar overall observations
were reported from the University of Basel [56
&&
].
In patients with ‘definitive’ PVN, BK viremia
titers correlate only moderately well with the





]. This latter observation casts fur-
ther doubt on the assumption that PCR-based BK-
viremia testing accurately reflects intrarenal events
and the severity of PVN in a linear fashion.
Thus, although the negative predictive value of
‘BKV replication/activation-based laboratory tests’,
that is, viruria and viremia, is excellent at higher
than 90% to rule out a diagnosis of PVN, the positive
predictive values are lower, ranging between 25%
and 75% [28,30].ADDITIONAL NEW TESTS
Urinary polyomavirus-haufen test
A diagnosis of ‘definitive’ PVN can now be rendered
noninvasively with a novel urine-based assay, called
the ‘urinary polyomavirus-haufen test’ (haufen is a
German term for heap or pile) (Fig. 4). Polyomavi-
rus-haufen form in the kidneys, that is, in virally
injured tubules, subsequent to polyomavirus repli-
cation, host cell lysis, and release of virions into(a) Urinary PV-haufen
σ = 0.86
ρ  = < 0.00001
(b) Urinary BKV PCR
σ = 0.48
ρ  = < 0.002
(c) Plasma BKV PCR
σ = 0.43
ρ  = < 0.006
(d) Urine Decoy cells
σ = 0.01
ρ  = 0.5
al BKV replication
): severity of intrarenal disease and corresponding titers of
xpression (quantitative screening test results – y-axis) with the
umber of SV40-T expressing tubular epithelial cells in a
: number of haufen/ml urine; (b) urine PCR for BK virus
umber of BKV copies/ml plasma; and (d) urine decoy cells:
lines with corresponding correlation coefficients (s) and
rved. www.co-transplantation.com 353
FIGURE 4. Voided urine sample with polyomavirus-haufen
in a patient with ‘definitive’ polyomavirus nephropathy.
Negative staining electron microscopy depicting a
characteristic polyomavirus-haufen in a voided urine sample.
Polyomavirus-haufen are tight cast-like three-dimensional
viral aggregates composed of at least six individual virions.
Note the large size of this polyomavirus-haufen resembling
a tubular cast. The diagnostic viral capsid substructure and
uniformity of virions allow for accurate identification by
electron microscopy (uranyl acetate stain: 100 000
magnification).
Pathologytubular lumens. The genesis of polyomavirus-hau-
fen depends upon high concentrations of uromo-
dulin (Tamm–Horsfall protein) and is very similar to
the formation of other intratubular casts, such as red
blood cell casts [70]. Once the polyomavirus casts
are flushed out of the kidney, they can be detected as
the so-called polyomavirus-haufen in voided urine
samples. They are specific biomarkers for intrarenal
viral disease with positive and negative predictive
values of higher than 90% (Fig. 5) [30].
Post-transplantation, polyomavirus-haufen
shedding follows a dynamic course – the test turns
from negative to positive at time of PVN onset,
remains positive during persistent disease, and
becomes negative again at the time of disease resol-
ution [30]. The titer of polyomavirus-haufen in the
urine (#haufen/ml urine) tightly correlates with the
degree of intrarenal polyomavirus replication (cor-
relation coefficient 0.86) (Fig. 3). Thus, quantitative
urinary polyomavirus-haufen testing can provide
additional information on the severity of PVN that
is relevant for diagnosis and monitoring of disease
resolution during follow-up [31
&&
].
Although experience is still limited and results
obtained with the urinary polyomavirus-haufen test354 www.co-transplantation.comrequire further validation, published data are very
promising. We finally seem to have an assay based
on a novel approach that not only accurately and
noninvasively identifies patients with ‘definitive’
PVN but also predicts the disease severity.Urinary VP1 mRNA measurements
In 2002, the team from Weill Cornell Medical
Center evaluated BKV VP1 mRNA levels in voided
urine samples from patients with and without PVN
[71]. Using a cutoff value of 6.55 log10 BKV VP1
mRNA copies per nanogram total RNA, the authors
reported a 94% sensitivity and specificity for PVN. In
2010, the group further validated their original find-
ings in a larger cohort of patients. They found that
urinary BKV VP1 mRNA expression as well as con-
currently elevated levels of mRNA for granzyme B
(>11 mRNA copies/mg total RNA) and proteinase
inhibitor-9 (>10 mRNA copies/mg total RNA) were
associated with deterioration of graft function in
PVN [57]. In a subsequent follow-up study limited
to patients with PVN, they described urinary cell
levels of mRNA for plasminogen activator inhibitor-
1 and serum creatinine levels at time of initial PVN
diagnosis to represent independent prognosticators
of graft failure [72
&&
]. These observations are intrigu-
ing because they offer not only additional strategies
to noninvasively diagnose ‘definitive’ PVN but also
to predict outcome. As elevated granzyme B levels
are typically found in patients with acute cellular
rejection, these data might indicate a higher than
expected prevalence of undiagnosed concurrent cel-
lular rejection contributing to graft deterioration in
some cases.POLYOMAVIRUS NEPHROPATHY:
DEFINITIVE AND PRESUMPTIVE
The terms ‘definitive’ and ‘presumptive’ PVN were
coined a decade ago. The prefix ‘definitive’ marks
cases with biopsy-proven intrarenal viral disease,
the term ‘presumptive’ was introduced for patients
with significant BKV replication but lack of histo-
logic proof of PVN, potentially due to false-negative
biopsy samples [56
&&
]. Transplant recipients with
‘presumptive’ PVN were believed to be at increased
risk for graft failure due to undiagnosed viral nephr-
opathy that carried an ominous prognosis a decade
ago [60]. In current clinical practice, ‘presumptive
PVN’ often equals ‘definitive PVN’ and the necessity
for therapeutic intervention [28,56
&&
]. This approach
undoubtedly potentially has some benefits in facil-
itating the prevention of PVN. However, reduction
of baseline immunosuppression as the common





FIGURE 5. Polyomavirus-haufen in patients with polyomavirus nephropathy. A cartoon image of a bivalved kidney (a)
highlighting an area of parenchyma sampled by renal biopsy (square box). An immunostain for the polyomavirus VP1 capsid
protein (b) shows strong staining of cast-like intratubular dense polyomavirus aggregates in injured renal tubules. These cast-
like viral structures are shed into the urine (c) and can serve as robust ‘structural’ urinary biomarkers for intrarenal disease, that
is, they give rise to a positive polyomavirus-haufen test (d) [30–32].
Polyomaviruses and disease Nickeleit and Singhacute rejection rates of 8–14% and subclinical rejec-
tion rates of 20–33% [36,73,74]. Notably, in 30%
of patients with BK viremia/‘presumptive’ PVN
reported in one series, preemptive reduction of
immunosuppression could not prevent the sub-
sequent development of ‘definitive’ PVN [74].
‘Presumptive’ and ‘definitive’ PVN – is it time
for a fresh contemporary approach? We believe the
following six findings are noteworthy and can guide
future discussions: definitive PVN in early disease
grades has good outcome; less than 50% of patients
with BK viremia develop intrarenal disease with
definitive PVN; BK viremia can originate from extra-
renal sites; the noninvasive urinary polyomavirus-
haufen test and mRNA test for BKV capsid protein
offer strategies to diagnose ‘definitive’ PVN and
disease severity; preemptive therapeutic inter-
vention in patients with BK-viremia/presumptive
PVN does not always prevent the development of
‘definitive’ PVN; and reduction of immunosuppres-
sion increases the risk of rejection.1087-2418 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseThese observations might pave the way for
future studies and targeted therapies focusing on
patient screening, an accurate definitive diagnosis
of early PVN, and personalized treatment of indi-
vidual patients with disease. Is the current ‘one
size-fits-all’ therapeutic approach in presumptive
PVN, triggered by nonstandardized PCR test results
and BK-viremia titers, still the best we have to offer?ONCOGENESIS
Over the past decade, approximately 20 publi-
cations reported high-grade invasive renal or uro-
thelial neoplasms expressing polyomavirus large
T antigen. These unusual and rare tumors occur in
organ transplant recipients, most often post-kidney
transplantation with or occasionally without a
history of PVN. They arise either in the (trans-
planted) kidney or the ureters/host bladder
[19,75,76]. Likely, oncogenesis in these neoplasms
is similar to that described in Merkel cell carcinomarved. www.co-transplantation.com 355
Pathologywith integration of polyomaviruses, presumably
BKV, into the human genome representing a
‘rare’ biological accident with dire consequences
[19,77,78]. There is no compelling evidence of viral
replication or productive polyomavirus infections
in the neoplasms and screening for BK viremia or
viruria is not suited for early tumor detection [79].SALIVARY GLAND DISEASE
BKV has been detected in tonsils and nasopharyng-
eal aspirates, usually representing latent viral infec-
tions. Recently, BKV has also been associated with a
sclerosing lymphocytic inflammatory salivary gland
disease found in a subgroup of HIV-infected indi-
viduals. Preliminary data suggest that certain
BKV strains preferentially infect salivary gland cells
over kidney cells and replicate with viremia and




Although BKV-associated salivary gland disease
does not seem to be of great clinical significance
post-transplantation, these data are, nevertheless,
intriguing. They suggest that replication of BKV
including viremia can originate outside the urinary
tract in immunocompromised patients not suffering
from PVN. Future studies are needed to further
investigate the significance of BKV replication in
salivary glands of organ transplant recipients.POLYOMAVIRUS DISEASE IN THE
SETTING OF BONE MARROW
TRANSPLANTATION
Post-hematopoietic stem cell transplantation
(HSCT) BKV activation and replication is associated
with various clinical findings ranging from asymp-
tomatic viruria, viremia, cystitis without hematuria,
and hemorrhagic cystitis with increased morbidity
and mortality [11
&&
,64,65,80]. BK viremia levels
higher than 4 log10 viral copies/ml mark an
increased risk for hemorrhagic cystitis in adult HSCT
recipients (odds ratio¼21) [81]. In the pediatric
HSCT population, Laskin et al. [11
&&
] showed that
BK viremia at any titer, but especially viral copy
numbers higher than 5 log10/ml plasma, independ-
ently predicted the development of hemorrhagic
cystitis in the first 100 days post-transplantation.
So far, standardized clinical definitions and screen-
ing guidelines have not been established [64].
As invasive biopsy procedures are generally
avoided in HSCT recipients because of increased risk
for severe bleeding, only little information is known
about the prevalence of PVN in this patient cohort,
and clinical experience is largely limited to few case
reports [82,83]. Does PVN possibly contribute to the356 www.co-transplantation.comdevelopment of chronic kidney disease seen in at
least 20% of children post-HSCT [84,85]? In a pilot
analysis, Laskin et al. found evidence of PVN, based
on a positive urinary polyomavirus-haufen test, in
five out of 11 pediatric patients with HSCT present-
ing with BK viremia and either with or without
concurrent cystitis (personal communication).
Thus, post-HSCT, PVN might be more common
than previously thought and the urinary polyoma-
virus-haufen test may prove to be of great clinical
value.CONCLUSION
PVN, historically considered to carry an ominous
prognosis, has evolved into a manageable and treat-
able disease. Patient screening protocols for risk
assessment and classification schemes to grade
PVN have led to the characterization of early disease
grades that are responsive to therapeutic interven-
tion and heal without significant chronic graft
injury. Novel diagnostic assays, such as the urinary
polyomavirus-haufen test, now provide accurate
noninvasive means to diagnose ‘definitive’ PVN
and assess disease severity in voided urine samples.
As BKV replication and BK viremia are seen in
patients without renal injury and viral nephrop-
athy, accurate noninvasive diagnostic testing
becomes crucial not only for personalized thera-
peutic intervention but also for enhancing knowl-
edge. Are so-called ‘presumptive’ and ‘definitive’
PVN the same disease entity?
The novel and currently only poorly understood
concept of immune reconstitution injury and graft
inflammation in patients with resolving PVN is an
area for future investigation. Is this a cellular
response driven by virus-specific T cells that is
self-limiting and beneficial for viral clearance? Or,
might this type of inflammation represent a more
harmful form of subclinical rejection with graft
infiltrating allospecific T cells detrimental to long-
term transplant integrity?
In immunocompromised patients, BKV is
associated with oncogenesis, possibly salivary gland
disease, and hemorrhagic cystitis. New members of
the polyomavirus family are being identified with
novel disease profiles. Thus, much has been learned
about polyomaviruses over the past 10 years but
many aspects still await further in-depth analysis.
Viremia and viruria alone cannot illuminate the
entire saga of polyomaviruses, viral nephropathy,
and human disease.Acknowledgements
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